Global
neuroendocrine
carcinoma therapeutics market is witnessing
significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine
carcinoma is a tumor that begins in neuroendocrine cells and can spread, or
metastasize, to other parts of the body. It starts in the hormone producing
cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many
organs including, lungs, brain and gastrointestinal tract. It is a very rare
cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight
loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and
anxiety. The risk factors of developing neuroendocrine cancer includes, age,
gender, family history, immune system suppression, arsenic exposure and sun
exposure. The diagnosis can be done by normal physical examination followed by
blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market/report-sample
The treatments available
for neuroendocrine tumor include chemotherapy, surgery and radiation therapy.
Chemotherapy comprises the drug’s use to destroy malignant cells by hindering
the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil
(Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors.
Many pharmaceutical companies have been working continuously for the
development of targeted therapy for the growth of neuroendocrine cancer market.
Geographically,
neuroendocrine carcinoma therapeutics market has been segmented into North
America, Europe, Asia Pacific and Rest of the World (RoW). According to
Cancer.Net, approximately 8,000 people are identified with neuroendocrine
cancer every year in the U.S. Several key players functioning in neuroendocrine
carcinoma therapeutics market are based in the U.S and therefore consider North
America as their main market for product launch and research and development investments.
Also, entrenched infrastructure and favorable reimbursement scenario are the
major factors accountable for the strengthening of North America’s neuroendocrine
carcinoma therapeutics market. Europe is the second largest market for neuroendocrine
carcinoma therapeutics, followed by Asia. Increasing prevalence of
neuroendocrine cancer in Asia Pacific along with the refining economic scenario
is expected to play an important role in driving the market growth in the
region.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market/toc-sample
Some of the key players operating in the global
neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Callisto Pharmaceuticals Pvt. Ltd., Biosynthema,
Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.
No comments:
Post a Comment